eHealth in Treatment of Gestational Diabetes (eMOMGDM) (eMOMGDM)
eHealth in Treatment of Gestational Diabetes - eMOM GDM -tutkimus (vaihe 2)
The overall aim of the eMOM GDM-project is to develop and evaluate a novel system to clinical decision making and patient behavior change in treatment of GDM, combining diet, physical activity, sleep, heart rate (e.g. stress), and glucose monitoring within a single system (the eMOM GDM application), and linking the developed application tool for the normal health care system in a new way.
In this second phase of the project, the effect of eMOM GDM application on maternal and neonatal outcomes will be evaluated in a randomized controlled study design. The follow-up study continues until 3 months postpartum.
Tutkimuksen yleiskatsaus
Tila
Tila
Ehdot
Ehdot
Interventio / Hoito
Interventio / Hoito
Yksityiskohtainen kuvaus
200 women with gestational diabetes will be randomized into the intervention and the control group at gestational week (GW) 24-28.
Participants in the intervention group will use the eMOM GDM -application one week/month until delivery.
The participants in the intervention and the control group visit study nurse 3 times in study period (at GW 24-28 and GW 35-37 and 3 months postpartum).
Both groups also receive regular antenatal care in maternity clinics and hospitals.
Maternal measurements at enrollment, and at 35-37 GW (both groups):
- Laboratory tests: fp-gluc, HbA1c, fp-insu, lipids, hs-CRP
- Fingertips glucose values from glucose meter (belong to normal antenatal care)
- Fasting blood samples for future analyses
- Weight, height, blood pressure (from the antenatal registry and study visits)
- Questionnaires: background (only at enrollment), diet (food frequency questionnaire), depression (EPDS), motivation (TSRQ+PCS), quality of life (15D)
- Physical activity and sedentary behavior with the hip-worn triaxial accelerometer (UKK RM 42)
- Physical activity and heart rate with Firstbeat Bodyguard
Measurements at Birth:
- Cord blood sample
- Placental weight
- Offspring birthweight, height, body composition (PEA POD Cosmed®)
Maternal measurements at 3 months postpartum:
- Laboratory tests: fp-gluc, HbA1c, fp-insu, lipids, hs-CRP
- fp-gluc, 2h postprandial value, as measured during oral glucose tolerance test (OGTT)
- Fasting blood samples for future analyses
- Firstbeat Bodyguard 2 measurement (3 days)
- Depression questionnaire (EPDS)
- Diet questionnaire (FFQ)
Protocol only for the intervention group
- eMOM GDM application: use: 1 application week + 3 normal care weeks repeatedly until delivery
The application includes:
-
continuous glucose monitor (CGM)
- fingertips glucose calibration according to CGM protocol (twice per day with Medtronic)
-
diet (digital food tracker)
- 3 days during one application week
- For ensuring the quality of food record a researcher will phone interview the participant based on her recordings. This is done after each recording period.
-
heartrate, stress and physical activity with the wrist-worn activity tracker (Vivosmart 3)
-
weight measured once a week
Data from the sensors
- Data from users' input to the application
- Technology acceptance questionnaire (UTAUT) after every application week
- Usability questionnaire, after four weeks usage of the eMOM GDM application
- Semi-structured interview
Opintotyyppi
Opintotyyppi
Ilmoittautuminen (Arvioitu)
Ilmoittautuminen
Vaihe
Vaihe
- Ei sovellettavissa
Yhteystiedot ja paikat
Opiskelupaikat
-
-
-
Helsinki, Suomi, 00029
- Helsinki University Hospital
-
-
Osallistumiskriteerit
Kelpoisuusvaatimukset
Kelpoisuusvaatimukset
Opintokelpoiset iät
Hyväksyy terveitä vapaaehtoisia
Sukupuolet, jotka voivat opiskella
Kuvaus
Inclusion Criteria:
- GDM diagnoses at 24-28 gestational weeks
Exclusion Criteria:
- type 1 or type 2 diabetes
- use of medication that influences glucose metabolism (such as continuous therapy with oral corticosteroids or metformin)
- multiple pregnancy
- physical disability
- current substance abuse
- severe psychiatric disorder (that complicates participation to the study)
- significant difficulty in cooperating (e.g. inadequate Finnish language skills)
Opintosuunnitelma
Miten tutkimus on suunniteltu?
Suunnittelun yksityiskohdat
- Ensisijainen käyttötarkoitus: Hoito
- Jako: Satunnaistettu
- Inventiomalli: Rinnakkaistehtävä
- Naamiointi: Kaksinkertainen
Aseiden lukumäärä
Aseet ja interventiot
Osallistujaryhmä / ArmOsallistujaryhmä / Arm |
Interventio / HoitoInterventio / Hoito |
|---|---|
|
Kokeellinen: Intervention (eMOM GDM application)
Participants in the intervention group will use the eMOM GDM -application one week/month. The participants will also receive regular antenatal care in maternity clinics and hospitals. In addition they will meet a study nurse three times during study period (at GW 24-28, at GW 35-37 and 3 mo postpartum). |
Participants in the intervention group will use the eMOM GDM -application one week/month. eMOM GDM application includes:
The sensors can be worn and the application used during the whole pregnancy (if a mother is interested in) |
|
Ei väliintuloa: Control
Participants in the control group will meet a study nurse 3 times during study period (at GW 24-28, at GW 35-37 and 3 mo postpartum). They also receive regular antenatal care in maternity clinics and hospitals. |
Mitä tutkimuksessa mitataan?
Ensisijaiset tulostoimenpiteet
Ensisijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Change in fasting glucose
Aikaikkuna: from gestational weeks 24-28 to gestational weeks 35-37
|
change in fasting glucose measured by Huslab (laboratory measurement) |
from gestational weeks 24-28 to gestational weeks 35-37
|
Toissijaiset tulostoimenpiteet
Toissijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Fingertips fasting glucose values
Aikaikkuna: from gestational weeks 24-28 up to delivery
|
Measured with Contour Next One |
from gestational weeks 24-28 up to delivery
|
|
Fingertips postbrandial glucose values
Aikaikkuna: from gestational weeks 24-28 up to delivery
|
Measured with Contour Next One |
from gestational weeks 24-28 up to delivery
|
|
Fingertips area under the glucose curve
Aikaikkuna: from gestational weeks 24-28 up to delivery
|
Measured with Contour Next One |
from gestational weeks 24-28 up to delivery
|
|
Gestational weight
Aikaikkuna: weight measured at gestational weeks 24-28 and at 35-37 and collected from antenatal card during whole pregnancy and up to delivery
|
Measured with Seca Mod 8787041649 (scale) and registered from antenatal card |
weight measured at gestational weeks 24-28 and at 35-37 and collected from antenatal card during whole pregnancy and up to delivery
|
|
Postpartum weight
Aikaikkuna: weight measured at 3 months postpartum
|
Measured with Seca Mod 8787041649 (scale) |
weight measured at 3 months postpartum
|
|
Physical activity level
Aikaikkuna: at gestational weeks 24-28, 35-37 and at 3 months postpartum
|
Measured with the accelerometers UKK RM42 and Firstbeat Bodyguard 2 |
at gestational weeks 24-28, 35-37 and at 3 months postpartum
|
|
Total diet
Aikaikkuna: at gestational weeks 24-28), 35-37 and at 3 months postpartum
|
Measured with a questionnaire (food frequencey questionnaire, FFQ) concerning participant's diet during previous month. FFQ contains questions about the frequency (number of times per day, week, or month) and the amount of foods consumed in units of common serving sizes. Nutritional quality of total diet is assessed based on calculated daily consumption of foods and intake of nutrients. Better nutritional quality is related to e.g. higher intake of fruits and vegetables, wholegrain cereals, fiber and unsaturated fat, and lower intake of added sugar and saturated fat. |
at gestational weeks 24-28), 35-37 and at 3 months postpartum
|
|
Neonatal body fat%
Aikaikkuna: one measure within 0-3 days after birth of the child
|
Measured with PEA POD Cosmed |
one measure within 0-3 days after birth of the child
|
|
Motivation to manage GDM
Aikaikkuna: at gestational weeks 24-28 and 35-37
|
Measured with a motivation questionnaire (TSRQ and PCS). Minimum value is 1 and maximum 5. The higher score means higher autonomous motivation to manage GDM. |
at gestational weeks 24-28 and 35-37
|
|
Percentage of participants on metformin treatment
Aikaikkuna: up to 42 gestational weeks
|
Percentage of participants need for metformin treatment |
up to 42 gestational weeks
|
|
Percentage of participants on insulin treatment
Aikaikkuna: up to 42 gestational weeks
|
Percentage of participants need for insulin treatment |
up to 42 gestational weeks
|
|
Newborn birthweight and macrosomia
Aikaikkuna: one measure at birth
|
Newborn birth weight and macrosomia (birthweight >4kg) |
one measure at birth
|
|
Incidence of neonatal hypoglycemia
Aikaikkuna: within a week from birth
|
Percentage of neonatal hypoglycemia requiring intravenous glucose |
within a week from birth
|
|
Incidence of newborn large for gestational age
Aikaikkuna: one measure at birth
|
Percentage of newborn with birthweight percentile > + 2 SD |
one measure at birth
|
|
Homeostatic Model Assessment for Insulin Resistance (HOMA-IR)
Aikaikkuna: gestational weeks 24-28, gestational weeks 35-37, 3 months postpartum
|
Change in HOMA-IR measured by Huslab (laboratory measurement), calculated as: fasting insulin (microU/L) x fasting glucose (nmol/L)/22.5. |
gestational weeks 24-28, gestational weeks 35-37, 3 months postpartum
|
|
2-h OGTT
Aikaikkuna: 3 months postpartum
|
2-hour blood glucose levels measured with OGTT (75g) |
3 months postpartum
|
|
Stress levels
Aikaikkuna: gestational weeks 24-28, gestational weeks 35-37, 3 months postpartum
|
Calculated based on dedicated HRV-based algorithm by Firstbeat. Defined as percentages. |
gestational weeks 24-28, gestational weeks 35-37, 3 months postpartum
|
|
Costs
Aikaikkuna: gestational weeks 24-28, 3 months postpartum
|
Costs of the intervention and treatment in healthcare. Defined as €/participant. |
gestational weeks 24-28, 3 months postpartum
|
Yhteistyökumppanit ja tutkijat
Sponsori
Sponsori
Yhteistyökumppanit
Yhteistyökumppanit
Julkaisuja ja hyödyllisiä linkkejä
Yleiset julkaisut
- Kyto M, Markussen LT, Marttinen P, Jacucci G, Niinisto S, Virtanen SM, Korhonen TE, Sievanen H, Vaha-Ypya H, Korhonen I, Heinonen S, Koivusalo SB. Comprehensive self-tracking of blood glucose and lifestyle with a mobile application in the management of gestational diabetes: a study protocol for a randomised controlled trial (eMOM GDM study). BMJ Open. 2022 Nov 7;12(11):e066292. doi: 10.1136/bmjopen-2022-066292.
- Maattanen S, Koivusalo S, Ylinen H, Heinonen S, Kyto M. The Effect of a Mobile App (eMOM) on Self-Discovery and Psychological Factors in Persons With Gestational Diabetes: Mixed Methods Study. JMIR Mhealth Uhealth. 2025 Jun 4;13:e60855. doi: 10.2196/60855.
Opintojen ennätyspäivät
Opi tärkeimmät päivämäärät
Opiskelun aloitus (Todellinen)
Opiskelun aloitus
Ensisijainen valmistuminen (Todellinen)
Ensisijainen valmistuminen
Opintojen valmistuminen (Arvioitu)
Opintojen valmistuminen
Opintoihin ilmoittautumispäivät
Ensimmäinen lähetetty
Ensimmäinen lähetetty
Ensimmäinen toimitettu, joka täytti QC-kriteerit
Ensimmäinen toimitettu, joka täytti QC-kriteerit
Ensimmäinen Lähetetty (Todellinen)
Ensimmäinen Lähetetty
Tutkimustietojen päivitykset
Viimeisin päivitys julkaistu (Todellinen)
Viimeisin päivitys julkaistu
Viimeisin lähetetty päivitys, joka täytti QC-kriteerit
Viimeisin lähetetty päivitys, joka täytti QC-kriteerit
Viimeksi vahvistettu
Viimeksi vahvistettu
Lisää tietoa
Tähän tutkimukseen liittyvät termit
Avainsanat
Muita asiaankuuluvia MeSH-ehtoja
- Urogenitaaliset sairaudet
- Endokriinisen järjestelmän sairaudet
- Naisten virtsa- ja sukupuolielinten sairaudet ja raskauden komplikaatiot
- Metaboliset sairaudet
- Raskauden komplikaatiot
- Glukoosiaineenvaihduntahäiriöt
- Diabetes mellitus
- Käyttäytyminen
- Ravitsemukselliset ja aineenvaihduntataudit
- Diabetes, raskausaika
- Motorinen toiminta
Muut tutkimustunnusnumerot
Muut tutkimustunnusnumerot
- HUS/2165/2018-Phase 2
Yksittäisten osallistujien tietojen suunnitelma (IPD)
Aiotko jakaa yksittäisten osallistujien tietoja (IPD)?
IPD-suunnitelman kuvaus
All data will be collected in Helsinki University Hospital Datalake from where pseudo-anonymised data can be requested until 2032 via a data sharing contract. Proposals should be directed to tietopalvelu(a)hus.fi.
IPD-jaon aikakehys
Until 2032
IPD-jakamista tukeva tietotyyppi
- STUDY_PROTOCOL
Lääke- ja laitetiedot, tutkimusasiakirjat
Tutkii yhdysvaltalaista FDA sääntelemää lääkevalmistetta
Tutkii yhdysvaltalaista FDA sääntelemää laitetuotetta
Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .